Quarterly report pursuant to Section 13 or 15(d)


6 Months Ended
Jun. 30, 2021
Inventory Disclosure [Abstract]  
Inventory Inventory
Inventory is comprised of unprocessed tissue, work-in-process, Avance® Nerve Graft, Axoguard® Nerve Connector, Axoguard® Nerve Protector, Axoguard® Nerve Cap, Acroval® Neurosensory and Motor Testing System, Axotouch® Two-Point Discriminator and supplies and is valued at the lower of cost (first-in, first-out) or net realizable value and consist of the following:
June 30,
December 31,
Finished goods $ 9,288  $ 8,876 
Work in process 482  751 
Raw materials 3,645  2,902 
Inventory $ 13,415  $ 12,529 
Included within Inventory is Avive® Soft Tissue Membrane ("Avive"). On May 17, 2021 the Company announced that it would suspend market availability of Avive effective June 1, 2021 pending ongoing discussions with the U.S. Food and Drug Administration (FDA) regarding the regulatory classification of Avive. The Company recorded a write-down of Avive inventory for an amount of $1,251 recorded in cost of goods sold in the condensed consolidated statement of operations related to this announcement.
The Company monitors the shelf life of its products and historical expiration and spoilage trends and writes-down inventory based on the estimated amount of inventory that may not be distributed before expiration or spoilage. For the six months ended June 30, 2021 and 2020, the Company had adjustments to the provision for inventory write downs of $2,455 (including the reserve for Avive of $1,251), and $1,624 respectively.